Over the past several weeks, The Cancer Letter has been running a series of articles that report on a past conflict between people at The University of Texas MD Anderson Cancer Center and Nobel Laureate Al Gilman, who led the scientific review teams of the then newly formed Cancer Prevention and Research Institute of Texas.
The FDA Oncologic Drugs Advisory Committee July 25 voted unanimously to set more rigorous standards for new trials for approval of perioperative indications of cancer drugs.
